The European Quality In Preclinical Data (EQIPD) project aims to increase the quality of data collected in pre-clinical studies. Therefore, the ultimate goal of EQIPD is to establish a quality management system that is fit-for-purpose for preclinical research and to develop standardised processes to ensure data quality leading to a reduction of research bias.
Role of PAASP
PAASP is the pioneer in providing support to improve preclinical research data quality and analysing the likelihood that preclinical research data are robust. Thus, PAASP experts will offer expertise and input for this novel quality system and PAASP is co-leading the word package on “New quality management system in emerging and classical technologies to improve preclinical robustness.”
This project combines the insights of academic groups focusing on drug development processes and industry-based researchers. Over 20 groups will participate in this €9.5 million over the next 3 years.
- The pharmaceutical industry partners are: Janssen Pharmaceutica, AbbVie, Boehringer Ingelheim, Novartis Pharma, Orion, Pfizer, PsychoGenetics, Institut de Recherches Servier, Hoffmann-La Roche, UCB Biopharma, and Sanofi-Aventis.
- The academic partners include the following universities: Edinburgh, Aberdeen, Imperial College London, Groningen, Radboud (Nijmegen), Tübingen, Munich, Berlin Charité, Ludwig-Maximilians, Mainz, and Bern.
- SMEs: Noldus, Porsolt, PsychoGenics, PAASP, Science Exchange and Sylics
EU-AIMS is funded as part of the Innovative Medicines Initiative (IMI), which in turn is part of the European Union’s Horizon 2020 program. IMI is the European Commission’s scheme for supporting precompetitive and public-private collaboration in the pharmaceutical industry.